224 related articles for article (PubMed ID: 31973229)
61. [Current status of molecular targeted therapies in hepatocellular carcinoma].
Suh SJ; Yim HJ
Korean J Gastroenterol; 2013 Mar; 61(3):136-46. PubMed ID: 23575232
[TBL] [Abstract][Full Text] [Related]
62. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Zhu AX
Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
[TBL] [Abstract][Full Text] [Related]
63. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
64. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks.
Kanthaje S; Makol A; Chakraborti A
Hepatol Res; 2018 Jan; 48(1):5-14. PubMed ID: 29055114
[TBL] [Abstract][Full Text] [Related]
65. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
66. Biomarkers for hepatocellular carcinoma based on body fluids and feces.
Guan MC; Ouyang W; Wang MD; Liang L; Li N; Fu TT; Shen F; Lau WY; Xu QR; Huang DS; Zhu H; Yang T
World J Gastrointest Oncol; 2021 May; 13(5):351-365. PubMed ID: 34040698
[TBL] [Abstract][Full Text] [Related]
67. Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy.
Pasini L; Ulivi P
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877735
[TBL] [Abstract][Full Text] [Related]
68. Systemic treatment for hepatocellular carcinoma.
Aggarwal M; Arain A; Jin Z
Chronic Dis Transl Med; 2018 Sep; 4(3):148-155. PubMed ID: 30276361
[TBL] [Abstract][Full Text] [Related]
69. Hepatocellular carcinoma extracellular vesicle ECG score as a diagnostic tool close to the ideal.
Słomka A; Mocan T; Willms AG; Lukacs-Kornek V; Kornek MT
Hepatobiliary Surg Nutr; 2023 Dec; 12(6):930-932. PubMed ID: 38115928
[No Abstract] [Full Text] [Related]
70. Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
Hepatology; 2024 Apr; 79(4):E127. PubMed ID: 38498370
[No Abstract] [Full Text] [Related]
71. Correction to "Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents".
Bose RJ; Kumar SU; Zeng Y; Afjei R; Robinson E; Lau K; Bermudez A; Habte F; Pitteri SJ; Sinclair R; Willmann JK; Massoud TF; Gambhir SS; Paulmurugan R
ACS Nano; 2023 Oct; 17(19):19470. PubMed ID: 37721437
[No Abstract] [Full Text] [Related]
72. Novel extracellular RNA biomarkers for early stage hepatocellular cancer.
Gondaliya P; Patel T
ExRNA; 2021 Dec; 3():. PubMed ID: 35874619
[No Abstract] [Full Text] [Related]
73. Hepatocellular carcinoma diagnosis and treatment: An overview.
Colquhoun SD; Wan YY
Liver Res; 2020 Dec; 4(4):159-160. PubMed ID: 33391846
[No Abstract] [Full Text] [Related]
74. Extracellular vesicles as potential biomarkers for diagnosis and recurrence detection of hepatocellular carcinoma.
Juratli MA; Pollmann NS; Oppermann E; Mohr A; Roy D; Schnitzbauer A; Michalik S; Vogl T; Stoecklein NH; Houben P; Katou S; Becker F; Hoelzen JP; Andreou A; Pascher A; Bechstein WO; Struecker B
Sci Rep; 2024 Mar; 14(1):5322. PubMed ID: 38438456
[TBL] [Abstract][Full Text] [Related]
75. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.
Pallozzi M; Di Tommaso N; Maccauro V; Santopaolo F; Gasbarrini A; Ponziani FR; Pompili M
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230554
[TBL] [Abstract][Full Text] [Related]
76. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.
Yao M; Yang JL; Wang DF; Wang L; Chen Y; Yao DF
World J Clin Cases; 2022 Apr; 10(11):3321-3333. PubMed ID: 35611205
[TBL] [Abstract][Full Text] [Related]
77. Extracellular Vesicles as Drug Delivery System for Treatment of Neurodegenerative Disorders: Optimization of the Cell Source.
Haney MJ; Zhao Y; Fallon JK; Yue W; Li SM; Lentz EE; Erie D; Smith PC; Batrakova EV
Adv Nanobiomed Res; 2021 Dec; 1(12):. PubMed ID: 34927169
[TBL] [Abstract][Full Text] [Related]
78. The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma.
Costanzi E; Simioni C; Varano G; Brenna C; Conti I; Neri LM
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34207985
[TBL] [Abstract][Full Text] [Related]
79. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.
Pandyarajan V; Govalan R; Yang JD
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418899
[TBL] [Abstract][Full Text] [Related]
80. Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations.
Klyachko NL; Arzt CJ; Li SM; Gololobova OA; Batrakova EV
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33271883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
